Pembrolizumab, a monoclonal antibody targeting programmed cell death-1 (PD-1), plays a pivotal role in modern oncology, including both adjuvant and advanced settings for renal cell carcinoma. This evidence concerns the gene PDCD1 and renal cell carcinoma.